📊 VVOS Key Takeaways
Is Vivos Therapeutics, Inc. (VVOS) a Good Investment?
Vivos faces critical financial distress with negative stockholders' equity (-$1.5M), unsustainable cash burn (-$17.6M FCF annually), and only $2M cash remaining—implying ~5 weeks of operational runway. Despite 16% revenue growth and healthy 60.4% gross margins, massive operating losses (-$19.9M) and technical insolvency create extreme downside risk requiring immediate capital infusion or restructuring.
Why Buy Vivos Therapeutics, Inc. Stock? VVOS Key Strengths
- Revenue growth of 16% YoY demonstrates market demand for surgical products
- Gross margin of 60.4% shows healthy pricing power and cost structure typical of medical devices
- Surgical instruments sector offers recurring revenue potential if financial viability is restored
VVOS Stock Risks: Vivos Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$1.5M indicates technical insolvency and balance sheet deterioration
- Critical liquidity crisis: current ratio of 0.24x with only $2M cash against -$15.3M operating cash burn
- Operating losses of -$19.9M exceed revenue of $17.4M—business model fundamentally unprofitable at current scale
- Going concern risk with estimated 5-7 weeks of cash runway at current burn rates without capital raise
Key Metrics to Watch
- Cash runway and monthly burn rate trajectory
- Capital raise announcements or debt restructuring
- Path to operating profitability and gross margin stability
Vivos Therapeutics, Inc. (VVOS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VVOS Profit Margin, ROE & Profitability Analysis
VVOS vs Healthcare Sector: How Vivos Therapeutics, Inc. Compares
How Vivos Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vivos Therapeutics, Inc. Stock Overvalued? VVOS Valuation Analysis 2026
Based on fundamental analysis, Vivos Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vivos Therapeutics, Inc. Balance Sheet: VVOS Debt, Cash & Liquidity
VVOS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vivos Therapeutics, Inc.'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $-2.22 indicates the company is currently unprofitable.
VVOS Revenue Growth, EPS Growth & YoY Performance
VVOS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.9M | -$1.9M | $-0.40 |
| Q2 2025 | $3.8M | -$1.9M | $-0.55 |
| Q1 2025 | $3.0M | -$3.8M | $-0.45 |
| Q3 2024 | $3.3M | -$1.7M | $-0.40 |
| Q2 2024 | $3.4M | -$1.7M | $-0.60 |
| Q1 2024 | $3.4M | -$1.7M | $-1.63 |
| Q3 2023 | $3.3M | -$1.7M | $-1.75 |
| Q2 2023 | $3.4M | -$1.7M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vivos Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VVOS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vivos Therapeutics, Inc. (CIK: 0001716166)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VVOS
What is the AI rating for VVOS?
Vivos Therapeutics, Inc. (VVOS) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VVOS's key strengths?
Claude: Revenue growth of 16% YoY demonstrates market demand for surgical products. Gross margin of 60.4% shows healthy pricing power and cost structure typical of medical devices.
What are the risks of investing in VVOS?
Claude: Negative stockholders' equity of -$1.5M indicates technical insolvency and balance sheet deterioration. Critical liquidity crisis: current ratio of 0.24x with only $2M cash against -$15.3M operating cash burn.
What is VVOS's revenue and growth?
Vivos Therapeutics, Inc. reported revenue of $17.4M.
Does VVOS pay dividends?
Vivos Therapeutics, Inc. does not currently pay dividends.
Where can I find VVOS SEC filings?
Official SEC filings for Vivos Therapeutics, Inc. (CIK: 0001716166) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VVOS's EPS?
Vivos Therapeutics, Inc. has a diluted EPS of $-2.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VVOS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vivos Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VVOS stock overvalued or undervalued?
Valuation metrics for VVOS: ROE of N/A (sector avg: 15%), net margin of -121.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VVOS stock in 2026?
Our dual AI analysis gives Vivos Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VVOS's free cash flow?
Vivos Therapeutics, Inc.'s operating cash flow is $-15.3M, with capital expenditures of $2.3M. FCF margin is -100.9%.
How does VVOS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -121.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.24 (avg: 2).